Abstract
A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 628-638 |
| Number of pages | 11 |
| Journal | Current Opinion in Pediatrics |
| Volume | 30 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jan 1 2018 |
| Externally published | Yes |
Fingerprint
Keywords
- Anthracycline
- Cardio-oncology
- Cardiotoxicity
- Childhood cancer
- Survivorship
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Cardiovascular disease in survivors of childhood cancer. / Bansal, Neha; Amdani, Shahnawaz M.; Hutchins, Kelley K.; Lipshultz, Steven E.
In: Current Opinion in Pediatrics, Vol. 30, No. 5, 01.01.2018, p. 628-638.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cardiovascular disease in survivors of childhood cancer
AU - Bansal, Neha
AU - Amdani, Shahnawaz M.
AU - Hutchins, Kelley K.
AU - Lipshultz, Steven E.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.
AB - A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.
KW - Anthracycline
KW - Cardio-oncology
KW - Cardiotoxicity
KW - Childhood cancer
KW - Survivorship
UR - http://www.scopus.com/inward/record.url?scp=85056496846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056496846&partnerID=8YFLogxK
U2 - 10.1097/MOP.0000000000000675
DO - 10.1097/MOP.0000000000000675
M3 - Article
C2 - 30124579
AN - SCOPUS:85056496846
VL - 30
SP - 628
EP - 638
JO - Current Opinion in Pediatrics
JF - Current Opinion in Pediatrics
SN - 1040-8703
IS - 5
ER -